**Posters**

**PWE-001 ARE FEMORAL TUNNelled CENTRAL VENOUS CATHETERS SAFE TO USE FOR HPn?**

1Arun Abraham*, 1David Sawbridge, 1Annabelle Coullier, 2Anjitee Teubner, 3Ashley Bond, 1Michael Taylor, 1,2Simon Lal. 1Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford, UK; 2School of Medical Science, University of Manchester, Manchester, UK; 3Royal Liverpool Hospital, Liverpool, UK

10.1136/gutjnl-2019-BSGAbstracts.332

**Background** Patients with Intestinal Failure (IF) require reliable intravenous access for provision of Parenteral Nutrition. Venous access for Home Parenteral Nutrition (HPN) patients with Type 3 IF can be compromised due to thrombosis of deep veins. Preferred choice of veins for central venous catheters are the supra cardiac veins. Femoral tunneled CVC are avoided due to concerns of catheter related bloodstream infection (CRBSI) and are considered as a last resort when all other thoracic CVC access is exhausted. We assess the outcomes of tunneled femoral catheters in our cohort of HPN patients.

**Methods** We did a retrospective analysis of a prospectively collected dataset of all HPN patients and venous access from January 2013 to December 2018 managed at a National HPN Unit. The details of venous access, complications of CVC, sex and details of stoma extracted from database.

**Results** In a cohort of 9 HPN patients with tunneled femoral CVC, 6 were females and 3 were males leading to a total of 8418 days. A total of 3 episodes of CRBSI were recorded in 1 patient. All of the 3 episodes (methicillin – sensitive *Staphylococcus aureus* (MSSA), Escherichia Coli and CNS) were successfully salvaged. The average no of days for femoral CVC was 935 days. The rate of CRBSI was 0.35 per 1000 catheter days. 8 patients had stoma or open abdominal wound. There were no episodes of ipsilateral femoral DVT. The CVC was replaced for 2 patients due to fracture of CVC.

**Conclusion** Tunned femoral CVC CRBSI rate (0.35) is comparable to thoracic veins CVC CRBSI rate(0.31) in our unit. Furthermore femoral access could be considered as a reliable access to provide HPN. It may be considered as an option if more than 2 thoracic deep veins are occluded to prevent complete occlusion of SVC. We feel tunneled femoral CVC is a safe option to consider for HPN commencing PN (lead time), initial hospital admission length, cancer type, mechanism of IF, and date of death. Co-morbidities were recorded using the validated Charlson index. Mechanism of IF was subdivided into 3 groups; obstruction (n=30), short bowel syndrome/high output fistula (n=22), and other (n=4). Cancer diagnoses were grouped into gynaec and peritoneal (n=26), gastrointestinal (GI) (n=18), and other (n=12). Categorical variables were compared using Fisher’s exact and continuous variables using Kruskal-Wallis. Survival rates were compared using Kaplan-Meier curves and cox regression. P<0.05 was used for significance.

**Results** 56 patients (mean age 57; 71.4% female) were identified during the study period. Patients with gynae/peritoneal primary were older when commencing PN (p=0.02) compared to other tumour groups. Patients with gynae/peritoneal cancers also had a longer lead time prior to starting PN compared to the other groups (Kruskal-Wallis p=0.01; Kaplan Meier p=0.04).

However once PN was started there was no difference in mortality between groups. 90 day mortality was 38.4% for gynae/peritoneal, 27.7% for GI, and 25.0% for others (p=0.633). 150 day mortality, the rate was 61.5% for gynae/peritoneal, 44.4% for GI, and 50.0% for others (p value 0.515). Kaplan-Meier curves appeared to diverge between gynaec/peritoneal and GI cancers although this wasn’t significant (p=0.56) and cox regression showed near identical survival between these groups (HR 1.02 p=0.97).

There was also no difference in mortality rates for different mechanisms of IF, 90 day mortality was 36.6% for obstruction, 31.8% for short bowel/fistula, and 0.0% for others (p=0.372). 150 day mortality was 60.0% for obstruction, 45.5% for short bowel/fistula, and 50.0% for others (p=0.647).

**Conclusions** Patients with slow growing gynaec/peritoneal cancers have been diagnosed with cancer for longer than other cancer types prior to commencing palliative PN. However once PN is commenced survival between groups in this cohort was similar. An extended follow up and a larger sample size may yet demonstrate significant differences. A prospective study is required to assess for other factors that may influence survival.

**PWE-002 HOME PARENTeral NUTRITION IN THE PALLiative PATIENT: A SINGLE CENTRE EXPERIENCE**

Jamal AI-Asry*, Catriona Bennett, Clare Donnellan, Peter Mooney. Leeds Teaching Hospitals Trust (LTH), Leeds, UK

10.1136/gutjnl-2019-BSGAbstracts.333

**Background** Few studies have assessed the benefit of nutritional support in advanced cancer patients. We aimed to investigate survival in patients receiving parenteral nutrition (PN) for intestinal failure (IF) in the palliative setting and identify factors associated with improved survival.

**Methods** Patients were identified from a database in an IF tertiary referral centre. Data were collected retrospectively for all cancer patients who commenced PN for a palliative indication between 01/01/2011 and 31/03/2018. These included; age on commencing PN, time from diagnosis (first MDT) to...